COMMUNIQUÉS West-GlobeNewswire

-
Streamline Today, Predict Tomorrow: MNDR's AI-Powered Health Operating System Optimizes Operations and Powers Predictive Healthcare
06/06/2024 - 15:28 -
Spectral AI Reaches 50% Enrollment at Burn Centers for U.S. Pivotal Burn Study
06/06/2024 - 15:14 -
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
06/06/2024 - 15:02 -
Aeroflow Health Announces Lactation Care Services are Now Available to Blue Cross Blue Shield Patients Across the Country
06/06/2024 - 15:00 -
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
06/06/2024 - 15:00 -
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
06/06/2024 - 15:00 -
Safety Shot Partners with Capital Drugs To Launch World’s First Beverage To Reduce Blood Alcohol Content in 300 Pharmacies Across the Country
06/06/2024 - 14:35 -
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
06/06/2024 - 14:30 -
Ipsen nomme Josep Catllà, en qualité de Vice-Président Exécutif, Chief Corporate Affairs Officer
06/06/2024 - 14:30 -
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
06/06/2024 - 14:30 -
SeaStar Medical Announces 25-for-1 Reverse Stock Split
06/06/2024 - 14:30 -
Retrieve Medical Announces Newly Issued Patent for Enhanced Problem List Management in EHR Systems
06/06/2024 - 14:30 -
MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
06/06/2024 - 14:30 -
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
06/06/2024 - 14:30 -
CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath
06/06/2024 - 14:30 -
Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Conference on June 12-13, 2024
06/06/2024 - 14:30 -
Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke
06/06/2024 - 14:15 -
RapidAI Wins 2024 MedTech Breakthrough Award For “Best Care Coordination Platform”
06/06/2024 - 14:00 -
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
06/06/2024 - 14:00
Pages